A 47-year-old woman presented with a 1-year history of spells characterized by slurring of speech, visual blurring, and on 2 occasions, loss of consciousness occurring 2 to 4 hours after meals and lasting 5 to 30 minutes. The spells were unrelated to fasting or physical activity. She also had milder spells of tremulousness, diaphoresis, and weakness occurring initially every other week but progressing to almost daily. Because the symptoms were alleviated with snacks or small drinks, the patient had begun consuming nuts continually throughout the day to prevent an episode. She had no history of prominent headaches, cutaneous flushing, chest pain, dyspnea, seizures, or psychiatric disorders.
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The patient had a history of type 2 diabetes mellitus and had undergone Roux-en-Y gastric bypass surgery 2 years previously for medically complicated obesity. Her diabetes resolved shortly after the surgery, and she had lost more than 50 kg. Aside from multivitamins, she was taking no other medications. She had been treated previously with metformin and subsequently with insulin, which were discontinued soon after bariatric surgery. No other members of the household took diabetic medications. Her medical history was otherwise unremarkable; specifically, she had no cardiac disease.
On physical examination, the patient's blood pressure was 105/63 mm Hg, pulse rate was 68/min and regular, and body mass index (calculated as weight in kilograms divided by the square of height in meters) was 26 kg/m 2 (presurgery, 46 kg/m 2 ). Well-healed surgical scars were noted on abdominal examination, along with a palpable nontender liver edge at the right costal margin. She had no murmurs or extra heart sounds, and findings on the remainder of her physical examination were normal. Carcinoid syndrome consists of cutaneous flushing, secretory diarrhea, and occasionally bronchospasm, all of which were absent in this patient. Patients with symptomatic pheochromocytoma generally have paroxysmal headaches, palpitations, diaphoresis, and hypertension. Notably, however, most pheochromocytomas are found incidentally during abdominal imaging. It would be unusual for atypical migraines to present with loss of consciousness or for symptoms to be alleviated by snacks. The periodicity of symptoms and temporal correlation to meals make atrial fibrillation unlikely. Symptoms of hypoglycemia vary among patients and are nonspecific. Some symptoms such as palpitations, tremulousness, nausea, and diaphoresis are adrenergic in nature, whereas others such as confusion, dizziness, dysphasia or dysarthria, loss of consciousness, or even seizures are neuroglycopenic.
The patient's symptoms were suggestive of hypoglycemia, and additional testing was ordered. 1 An oral glucose tolerance test is usually done to evaluate hyperglycemia and has little value in the work-up of hypoglycemic patients.
Because of the nonspecificity of symptoms, the diagnosis of hypoglycemia requires the demonstration of Whipple's triad: (1) symptoms compatible with hypoglycemia, (2) documentation of a concurrent low serum glucose level during one such episode, and (3) rapid resolution of symptoms with administration of glucose.
Although the patient's symptoms were suggestive of hypoglycemia, a low serum glucose level had not been documented during one of her spells. Because the patient reported frequent symptoms, she was instructed to go to one of the several nearby venipuncture sites to have blood samples obtained during a typical spell. Approximately 2 hours after breakfast the following day, the patient experienced a spell and immediately presented to a venipuncture facility for blood tests, which revealed a serum glucose level of 51 mg/dL. Once hypoglycemia has been documented, the next question is whether it is insulin mediated or non-insulin mediated. Non-insulin mediated causes of hypoglycemia include adrenal insufficiency, growth hormone deficiency, liver and renal disease, prolonged starvation, and certain medications such as quinine and gatifloxacin. During episodes of low serum glucose concentrations, insulin secretion by pancreatic islets should decrease. An elevated serum insulin level (>3 µIU/mL) during a spell with a concurrently low serum glucose concentration (<50 mg/dL) indicates an inappropriately high insulin level, hyperinsulinemic hypoglycemia. C peptide is cleaved from proinsulin during insulin production and would be a useful determinant of whether the hyperinsulinism is endogenous or exogenous. Because commercially available insulin preparations use insulin and not its precursor, C-peptide levels would not be expected to be high after the administration of insulin. Therefore, hypoglycemia from surreptitious insulin administration would manifest as elevated insulin levels with a low C-peptide level, while an insulinoma would cause nonsuppressed insulin and C peptide.
Although growth hormone deficiency can cause hypoglycemia, this is rare in the adult population. Because nothing in this patient's history suggests that she is growth hormone deficient, insulin-like growth factor I measurement would not yield helpful information. A sulfonylurea screen would detect the presence of this group of medications in the body, which is important because sulfonylureas are islet secretagogues that stimulate endogenous insulin secretion. Therefore, sulfonylurea-mediated hypoglycemia would manifest with elevated insulin and C-peptide levels. Another test that should be conducted at least once during the evaluation of hypoglycemia is an insulin antibody titer. Patients with autoimmune hypoglycemia have antibodies that bind circulating insulin and act as a reservoir. Insulin is slowly released late postprandially, 2 causing hypoglycemia. This condition is exceedingly rare.
Our patient's blood test during hypoglycemia showed an insulin level of 8.3 µIU/mL, a proinsulin concentration of 64 pmol/L, and a C-peptide level of 7.2 ng/mL, all inappropriately elevated in view of the hypoglycemia. These findings suggest a state of insulin-mediated hypoglycemia. Insulin antibodies were absent, and a sulfonylurea screen yielded negative results. The patient underwent a mixed-meal study in which she brought and consumed a meal that would most likely reproduce her spells (a cheeseburger and a regular soda) while being monitored in the clinic. This study reproduced the hypoglycemia, with a nadir serum glucose level of 36 mg/dL at 2 hours and inappropriately elevated insulin and C-peptide concentrations (Table 1) . In acute hypoglycemia, insulin levels are normally less than 3 µIU/mL, and C-peptide levels are less than 0.6 ng/mL. On the basis of these results, endogenous insulin-mediated hypoglycemia was diagnosed. The next task was to determine the exact cause of the condition in our patient. The patient had no history suggestive of adrenal insufficiency, pheochromocytoma, or multiple endocrine neoplasia, type I, in which an insulinoma may occur in addition to tumors of the parathyroid and pituitary glands. Therefore, obtaining cortisol or catecholamine measurements or performing expensive genetic tests would provide little ben- efit. Because endogenous insulin-mediated hypoglycemia had already been diagnosed, the next step is to localize the source of the problem by CT or ultrasonography. A 72-hour fasting study is unnecessary in this patient since true hypoglycemia was documented by previous studies. The patient underwent CT and transabdominal ultrasonography, both of which revealed only postoperative changes from her previous gastric bypass surgery and a tiny left renal cyst. Because conventional pancreatic imaging studies yielded negative results, a selective arterial calcium stimulation test was performed. Right hepatic vein insulin levels were measured after infusion of calcium into the superior mesenteric, gastroduodenal, and splenic arteries. Postinfusion insulin levels were found to be abnormal in all 3 arteries.
At this point in the evaluation

Which one of the following is the most likely explanation for the results obtained by selective arterial calcium stimulation? a. Insulinoma in the tail of the pancreas b. Insulinoma in the head of the pancreas c. Insulinoma in the uncinate process d. Diffuse pancreatic disease e. Insulinoma with hepatic metastasis
The basis for the selective arterial calcium stimulation test is that insulinomas or islet hyperplasia can be stimulated to secrete insulin after an infusion of calcium whereas normal islets cannot. This procedure helps to localize the hyperfunctioning tissue because the splenic artery perfuses primarily the tail of the pancreas, the gastroduodenal artery supplies the head of the pancreas and secondarily the uncinate process, and the superior mesenteric artery supplies the uncinate process and secondarily the head of the pancreas. Insulinoma in any of these locations would produce a positive result in 1 area; positive findings in all 3 areas suggest a diffuse pancreatic process. The selective arterial calcium stimulation test is not used to evaluate hepatic metastasis of insulinomas.
Our patient subsequently underwent surgical pancreatic exploration. During the procedure, the pancreas was palpated in its entirety, and no masses were felt. Intraoperative pancreatic ultrasonography yielded negative results. Consequently, a distal pancreatectomy was performed. Examination of the resected distal pancreas revealed hypertrophied islets of Langerhans with pleomorphic nuclei in islet cells and occasional islets budding from pancreatic ducts, consistent with nesidioblastosis. The combination of the patient's history and the biochemical and pathologic findings thus provided the diagnosis of noninsulinoma pancreatogenous hypoglycemic syndrome (NIPHS). No tumor was identified. Eight months after surgery, our patient remained free of symptoms.
DISCUSSION
This case highlights how hypoglycemia remains a challenging problem for primary care physicians and clinical endocrinologists alike. Serum glucose values in hypoglycemic ranges have been well documented in healthy subjects. In addition, symptoms attributable to hypoglycemia are notoriously nonspecific. Therefore, the diagnosis of a true hypoglycemic pathologic state requires not only numerical but also consistent historical data. A stepwise approach is usually needed to evaluate and treat patients presenting with true hypoglycemia.
Once hypoglycemia has been identified, insulin levels, markers of endogenous insulin production, and antibodies should be investigated. Another useful test is measurement of serum β-hydroxybutyrate, an insulin surrogate. Insulin, a potent antilipolytic agent, decreases during a 72-hour fast. This decrease would result in slowly increasing levels of ketones in the plasma as the body undergoes lipolysis and ketogenesis from alternative fuels such as fat. In a healthy patient undergoing a fast, increasing levels of β-hydroxybutyrate suggest a state of decreased insulin levels in the body. Two successive β-hydroxybutyrate levels above the 18-hour concentration, or a level greater than 2.7 mmol/L, have good negative predictive value for the 72-hour fast. 3 After documentation of endogenous hyperinsulinemic hypoglycemia, pancreatic imaging is the next step. Because insulinomas are highly vascular in the arterial phase, the test of choice is usually abdominal CT, which has a sensitivity of 66% or higher. 4 At our institution, radiologists can detect 63% of insulinomas prospectively and 83% retrospectively. 5 The yield of transabdominal ultrasonography depends considerably on operator expertise; in experienced hands, it is able to detect up to two thirds of insulinomas. 4, 6 Visualization of tumors in the body and tail of the pancreas is more difficult and may be limited by the patient's body habitus. Alternatively, endoscopic ultrasonography reportedly has higher sensitivity (80%-90%) and is able to localize tumors as small as 2 mm but is more labor intensive and invasive. Because head-to-head comparisons of these modalities are lacking, these results may be biased.
If conventional imaging studies yield negative results, a selective arterial calcium stimulation test may be indicated. Under fluoroscopic guidance, the right hepatic vein is catheterized to obtain serial blood samples for insulin measurements while the gastroduodenal, superior mesenteric, and splenic arteries are individually infused with 0.025 mEq/kg of calcium. A positive test result is indicated by a doubling or, better, a tripling of the insulin levels after the infusion. Because this test is invasive and has some associated risk, it is not done routinely except when conventional imaging techniques have failed to localize a pancreatic lesion in a patient with biochemically proven endogenous hyperinsulinemic hypoglycemia.
Although insulinomas have long been recognized as a cause of hypoglycemia, the disease entity termed noninsulinoma pancreatogenous hypoglycemic syndrome was described only recently (in 1999). 7 Biochemically, this condition resembles insulinomas in that they are both endogenous hyperinsulinemic hypoglycemic syndromes. The pathogenesis is still unknown, but the pathophysiology appears to be related not to an autonomously functioning islet tumor but rather to enlargement of islet size. Consequently, the insulin hypersecretion occurs in response to meals. Patients often present with hypoglycemia 2 to 4 hours after eating, whereas patients with insulinoma usually become symptomatic while fasting. Because the abnormality is at a microscopic level, the results of conventional imaging techniques used for the evaluation of patients with insulinomas often are negative.
Recently, Service et al 8 described an increased incidence of NIPHS in patients who have undergone gastric bypass surgery. The reason for this increased incidence is unclear, although some have postulated that increased delivery of food to the small bowel may trigger factors such as glucagon-like peptide 1 that may stimulate the growth of pancreatic islets, seen histologically as nesidioblastosis. 9 Interestingly, however, nesidioblastosis has been found in up to a third of pancreata in autopsy series involving subjects with no history of hypoglycemia.
Surgical debulking is the only definitive treatment for NIPHS and successfully ameliorates symptoms of hypoglycemia in most patients. 10 Because experience with medical therapy such as diazoxide and somatostatin ana- Since the initial description of NIPHS, it is being reported increasingly by many medical centers. Given the frequency of gastric bypass surgery worldwide, the incidence of NIPHS is expected to increase. Therefore, practicing clinicians should have a keen sense of suspicion for this disorder when evaluating patients with spells of undetermined origin.
